Similar articles for PMID: 29423337

Year	Number of Results
1976	1
1987	1
1988	1
1998	2
1999	1
2001	1
2002	2
2003	7
2004	2
2005	4
2006	2
2007	3
2008	3
2009	4
2010	5
2011	4
2012	9
2013	14
2014	12
2015	10
2016	5
2017	9
2018	13
2019	5
2020	10
2021	7
2022	4
2023	1
2024	0

1

Istradefylline for Restless Legs Syndrome Associated with Parkinson's Disease.

Nuermaimaiti M, Oyama G, Kasemsuk C, Hattori N. Nuermaimaiti M, et al. Tremor Other Hyperkinet Mov (N Y). 2018 Jan 8;8:521. doi: 10.7916/D86H5R1H. eCollection 2018. Tremor Other Hyperkinet Mov (N Y). 2018. PMID: 29423337 Free PMC article. No abstract available.

2

Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.

Paton DM. Paton DM. Drugs Today (Barc). 2020 Feb;56(2):125-134. doi: 10.1358/dot.2020.56.2.3098156. Drugs Today (Barc). 2020. PMID: 32163528 Review.

3

Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.

Perez-Lloret S, Merello M. Perez-Lloret S, et al. Expert Opin Pharmacother. 2014 Jun;15(8):1097-107. doi: 10.1517/14656566.2014.903924. Epub 2014 Mar 27. Expert Opin Pharmacother. 2014. PMID: 24673462 Review.

4

Occupancy of adenosine A_2A receptors by istradefylline in patients with Parkinson's disease using ¹¹C-preladenant PET.

Ishibashi K, Miura Y, Wagatsuma K, Toyohara J, Ishiwata K, Ishii K. Ishibashi K, et al. Neuropharmacology. 2018 Dec;143:106-112. doi: 10.1016/j.neuropharm.2018.09.036. Epub 2018 Sep 22. Neuropharmacology. 2018. PMID: 30253174 Clinical Trial.

5

Does istradefylline really have a dystonic mechanism?

Kataoka H, Sugie K. Kataoka H, et al. J Neurol Sci. 2018 May 15;388:233-234. doi: 10.1016/j.jns.2018.03.020. Epub 2018 Mar 14. J Neurol Sci. 2018. PMID: 29559176 No abstract available.

6

Istradefylline (Nourianz) for Parkinson's disease.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Feb 10;62(1591):20-23. Med Lett Drugs Ther. 2020. PMID: 32022788 No abstract available.

7

The effect of istradefylline for Parkinson's disease: A meta-analysis.

Sako W, Murakami N, Motohama K, Izumi Y, Kaji R. Sako W, et al. Sci Rep. 2017 Dec 21;7(1):18018. doi: 10.1038/s41598-017-18339-1. Sci Rep. 2017. PMID: 29269791 Free PMC article.

8

Istradefylline for the treatment of Parkinson's disease.

Park A, Stacy M. Park A, et al. Expert Opin Pharmacother. 2012 Jan;13(1):111-4. doi: 10.1517/14656566.2012.643869. Expert Opin Pharmacother. 2012. PMID: 22149371 Review.

9

The role of istradefylline in the Parkinson's disease armamentarium.

Müller T. Müller T. Expert Opin Pharmacother. 2023 May;24(7):863-871. doi: 10.1080/14656566.2023.2201374. Epub 2023 Apr 18. Expert Opin Pharmacother. 2023. PMID: 37029952 Review.

10

Istradefylline - a first generation adenosine A_2A antagonist for the treatment of Parkinson's disease.

Jenner P, Mori A, Aradi SD, Hauser RA. Jenner P, et al. Expert Rev Neurother. 2021 Mar;21(3):317-333. doi: 10.1080/14737175.2021.1880896. Epub 2021 Feb 22. Expert Rev Neurother. 2021. PMID: 33507105 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

121 results

Results by year